Premium
Phase II trial of tamoxifen in metastatic carcinoma of the prostate
Author(s) -
Glick John H.,
Wein Alan,
Padavic Kristin,
Negendank William,
Harris David,
Brodovsky Harvey
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820401)49:7<1367::aid-cncr2820490711>3.0.co;2-8
Subject(s) - medicine , tamoxifen , prostate , antiestrogen , carcinoma , urology , prostate cancer , oncology , cancer , breast cancer
Fifty‐one patients with advanced metastatic carcinoma of the prostate were treated with the antiestrogen tamoxifen. Thirty‐eight of these patients were refractory to prior hormonal manipulation with estrogens and/or orchiectomy, and five (13%) achieved an objective response (partial regression or stable disease using the National Prostate Cancer Project criteria). Median survival of the responders was significantly longer than that of the nonresponders ( P < 0.05). An additional 13 patients who had not previously received hormonal manipulation were treated with tamoxifen; one partial response and three disease stabilizations were noted. Response was separately evaluated for 15 patients with objectively measurable lesions using standard Phase II response criteria. Only 1/15 (7%) partial response and 3/15 (20%) disease stabilizations were documented. Subjective benefit in terms of significant pain relief was noted in 17/50 (34%) of patients. Toxicity was mild, but two possible “tumor flares” were noted. These results do not support the continued investigation of tamoxifen in advanced carcinoma of the prostate.